Schizophrenia biotech Minerva Neurosciences files for a $69 million IPO

By
A A A

Minerva Neurosciences, a clinical stage biotech developing treatments for CNS diseases, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company has four candidates designed to treat schizophrenia, major depressive disorder, insomnia and Parkinson's disease. The Cambridge, MA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol NERV. Minerva Neurosciences initially filed confidentially on February 14, 2014. Jefferies is the sole bookrunner on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: NERV

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com